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Abstract 
Brain neurochemistry and cognition performance are thought to decline with age. Accumulating data indicate 
that similar events occur after prolonged methamphetamine (MA) exposure. Using the rat as a model, the 
present study was designed to uncover common alteration patterns in brain neurochemistry and memory 
performance between aging and prolonged MA exposure. To this end, animals were treated with a chronic 
binge MA administration paradigm (20 mg/kg/day from postnatal day 91 to 100). Three-age control groups 
received isovolumetric saline treatment and were tested at the MA age-matched period, and at 12 and 20 
months. We observed that both MA and aged animals presented a long, but not short, time impairment in 
novelty preference and an increased anxiety-like behavior. Neurochemical analysis indicated similar MA- 
and age-related impairments in dopamine, serotonin and metabolites in the striatum, prefrontal cortex and 
hippocampus. Thus, the present data illustrate that MA may be used to mimic age-related effects on 
neurotransmitter systems and advocate MA treatment as a feasible animal model to study neuronal 
processes associated with aging. 
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1. Introduction 
Methamphetamine (MA) is a highly addictive psychostimulant. Abuse of MA has increased dramatically to 
epidemic proportions worldwide and is an escalating public health issue (Cretzmeyer et al., 2003). MA abuse 
is associated with frontostriatal neurotoxicity (Salo et al., 2009), with morphometric alteration in brain areas 
such as hippocampus and cortex (Eisch et al., 1998 and Harvey et al., 2000), together with cognitive and 
decision-making impairments (Kalechstein et al., 2003, Nordahl et al., 2003, Scott et al., 2007 and Simon et 
al., 2004). Despite the publication of numerous studies in rodent models, knowledge of the types and the 
duration of behavioral alterations resulting from extended administration of MA remain limited (Marshall et 
al., 2007, Nagai et al., 2007 and Schroder et al., 2003). Although a number of studies report particular 
cognitive impairments in subjects with a history of amphetamine abuse (Meredith et al., 2005), distinguishing 
drug effects from other genetic and environmental conditions of these individuals is a complex task. 
In rodents, MA decreases various indices of dopamine terminal integrity in the striatum as the preferential 
target (Hotchkiss and Gibb, 1980 and Ricaurte et al., 1982). The molecular mechanisms of MA toxicity are 
precipitated by its rapid entry into the CNS, followed by its influx into monoaminergic vesicles. This leads to 
the displacement of monoamines into the cytoplasm and their release into the synaptic cleft, inducing an 
extracellular increase of dopamine (DA) (Melega et al., 1995 and Nash and Yamamoto, 1992) and a 
redistribution of cytosolic DA (Cubells et al., 1994 and Jones et al., 1998). MA triggers DA release from the 
cytosol to the extracellular space by means of reverse transport through DA transporters (DAT). Vesicular 
monoamine transporter 2 (VMAT2) also plays an important role in the MA-induced toxicity. Studies using 
VMAT2 knockout mice showed a higher rate of manifestations of MA neurotoxicity compared with wild type 
mice (Fumagalli et al., 1999). Oxidation of DA produces H2O2 via monoamino oxidase A (MAO-A) (Capela 
et al., 2009 and Graham, 1978) leading to a decrease number of DATs (Fleckenstein et al., 
1997 and Metzger et al., 2000). Prolonged access to MA induces substantial nerve terminal degeneration 
within dopaminergic neurons (Ricaurte et al., 1983a and Ricaurte et al., 1983b), together with depletions in 
the majority of DA-related markers (Hotchkiss and Gibb, 1980 and Koda and Gibb, 1973). Reduction in the 
extracellular content of DA and metabolites has been demonstrated following MA exposure (Robinson et al., 
1990). Even early developmental exposure to MA has been correlated with long-term dopaminergic deficits 
(Bubenikova-Valesova et al., 2009). To a lesser extent, repeated MA exposure also affects serotonergic 
terminals. The drug may cause a reduction in the concentration of serotonin (5HT) and its respective 
metabolites, a decrease in the number of 5HT transporter binding sites, and a reduction in the activity of 
tryptophan hydroxylase (Ricaurte et al., 1980 and Wagner et al., 1980a). 
The senescence process is characterized by a time-dependent functional decline of both tissues and organ 
systems, which is related to biochemical, physiological, genetic and anatomical degeneration (Carnes et al., 
2008 and Troen, 2003). It is known that drug abusers present several signs of accelerated aging. Indeed, 
age-related development and a more rapid evolution of various co-morbidities are observed in chronic 
consumers of drugs of abuse (Carvalho, 2009). Long-term abuse of psychostimulants is linked to premature 
atherosclerosis, ventricular hypertrophy, cardiomyopathies (Dowling et al., 2008) and kidney failure 
(Vupputuri et al., 2004). Moreover, evidence suggests that memory dysfunction is a consequence of aging 
(for review see Erickson and Barnes, 2003). Alterations in the neurochemistry of the different brain regions 
may offer valid cues to investigate the processes implicated in memory loss (Luine et al., 1990). 
It has long been known that exposure to MA impairs cognition (Belcher et al., 2006, Belcher et al., 
2008,Bisagno et al., 2002, Schroder et al., 2003 and White et al., 2009). However, the acute high doses 
delivered in the majority of studies hardly mimic the human drug abuse pattern. A recent report showed that 
extended daily access to MA (6 h) impaired novel object recognition memory, but the effect was not observed 
after only short periods (1 or 2 h) of exposure (Rogers et al., 2008). 
When working with rodent models, memory components can be evaluated using the object recognition (OR) 
task (Ennaceur et al., 2005). This task measures recognition memory based on spontaneous exploration 
behavior and innate tendency to novelty preference. The OR task has several advantages in terms of relating 
the neurochemical profile to memory performance: First, the task does not use a positive (e.g., food/water 
rewards) or negative (e.g., electrical shocks) reinforcement, which may interfere with factors such as anxiety 
levels. Second, animals are not required to learn contingency rules to perform the tasks. Third, stress-related 
confounding variables can be minimized since animals do not encounter stressful circumstances, such as 
forced swimming in the Morris water maze (Ennaceur et al., 1997). 
Since the nigrostriatal DA system is impaired after extended MA exposure and during the senescence 
process, the present study was designed to uncover common alteration patterns in brain neurochemistry 
and memory performance between chronological aging and prolonged MA exposure. Moreover, we 
endeavor to contribute to the development of a model that mimics the age-related effects to the 
neurotransmitter systems and to the recognition memory of the rat. 
2. Materials and methods 
2.1. Experimental design and drug administration 
Forty-four adult male Wistar rats from Charles Rivers (Barcelona, Spain) were used. All experiments were 
performed in a licensed environmental controlled room (respecting the Guidelines of the European Union 
Council 86/609/EU and Portuguese Law Decreto-Lei N° 1005/92) at the Instituto de Biologia Molecular e 
Celular (IBMC), Universidade do Porto. Food and water were freely available. (+)-MA hydrochloride (Sigma–
Aldrich, St. Louis, MO, USA) was dissolved in saline (NaCl, 0.9%) and administrated in a volume of 1 mL/kg 
injected intraperitoneally. Changes in body weight were registered daily. Each group consisted of at least 6 
animals. Rats were assigned to their respective groups at postnatal day (PND) 60 (2 animals of the same 
experimental group per cage). Treated rats received 5 mg/kg of MA every 2 h for a period of 6 h (i.e., 4 
injections) each day between PND 91 and 100. Between injection, stereotypies were observed, 
nevertheless, they were absent at the time of all behavioral measurements. The three groups (MA age-
matched, and chronologically aged 12 months and 20 months rats) received an isovolumetric dose of saline 
following the same age and injection pattern to equal stress induction produced in the administration of MA. 
The dose chosen corresponded well with previous work by our group (Melo et al., 2010), and by the Vorhees 
group where they investigated the effect of MA exposure, comprising 4 doses per day of 5 mg/kg of MA at 
2 h intervals, from PND 51 to 60 after which long-term spatial and sequential learning deficits were observed 
(Vorhees et al., 2005). 
2.2. Habituation 
On the first day after the last administration of MA, animals were exposed for the first time to the experimental 
room and the test apparatus. The first session served as an anxiety test, which was followed by four other 
habituation trials. An object was placed in the center of the arena. On habituation days 1–5, each rat was 
placed in the arena and the behavior was recorded for 10 min. The MA age-matched control group followed 
the same protocol. The two groups of aged animals were tested at the respective time point (12 or 20 
months) following the same protocol. 
2.3. Object recognition task 
The OR task used in this study (Fig. 1) was adapted from previous work (Ennaceur et al., 2005). All trials 
were performed in the dark period and in an open field arena 
(width × length × height = 60 cm × 80 cm × 40 cm) made of gray PVC. Intensity of light (100 lx) was carefully 
controlled to illuminate the floor of the chamber evenly. The objects to be discriminated were made of a 
biologically neutral material, such as plastic (cube with 6 cm × 6 cm × 6 cm), metal (pyramid with 10 cm in 
the base and 10 cm of height) or glass (cylinder with 6 cm of diameter and 10 cm of height), and fitted to the 
surface of the arena so that the animals could not move them around. Between all trials the surface of the 
arena and objects was cleansed with neutral soap (Extran, Merck, Darmstadt, Germany). All trials were 
videotaped with a SONY DCR-SR290E camcorder, suspended above the test arena, and analyzed 





The OR test was performed on the sixth and seventh day after the beginning of the habituation process. It 
consisted of a first session of a 3-min sample trial and two different retention trials. The short retention time 
was considered 15 min and the long retention time 24 h. During the sample trial, two identical objects were 
placed at one end of the open field arena, 10 cm away from the sidewall. The total amount of time that the 
animals spent exploring the objects during the 3 min was recorded. In each of the two different retention 
trials, a new object replaced one of the familiar objects. The time spent by the animal exploring the familiar 
and the new object was recorded for a 3 min duration. 
2.4. Behavioral measurements 
The basic measures were the time spent by the rats exploring objects during the first habituation trial, during 
the sample phase and during the choice phase. Exploration of an object was defined as directing the nose 
to the object at a distance of approximately 2 cm and/or touching it with the nose. Conversely, turning around 
or sitting on the object was not considered as exploratory behavior. Considering the overall exploration of 
objects in the different trials, the following measurements were analyzed: the frequency of approaches, 
which refers to the number of times a rat approached each object; the total object exploration, which refers 
to the amount of time spent by a rat exploring the objects; the object exploration, which refers to the amount 
of time spent by a rat exploring each object; the object exploration frequency, which refers to the number of 
times a rat explored each object. The discrimination index measures the response of animals in exploring 
novelty and familiarity and is calculated by the product of the difference (subtraction) between time and 
frequency of exploration of new and familiar objects. A value that is significantly above zero describes 
animals exploring more the novel than the familiar object. A value that is significantly below zero describes 
animals exploring more the familiar than the novel object. 
2.5. Neurochemistry: monoamines and metabolites 
The day after completion of behavioral studies, six animals from each experimental group were used for 
neurochemical analysis. Rats were sacrificed by decapitation and the brains rapidly dissected on ice under 
dim light and stored at −70 °C until determination. The striatum, prefrontal cortex and hippocampus were 
used in this study. The different brain regions were ultrasonicated (Sonifier W-250, Branson Ultrasonics, 
Danbury, CT) in 200 μL of ice-cold 0.2 M perchloric acid. The homogenate was centrifuged at 
13,000 × gduring 15 min at 4 °C and the supernatant was filtered thought a 0.2 μm Nylon-66 microfilter. 
Aliquots of 50 μL were analyzed by high-performance liquid chromatography (HPLC) with electrochemical 
detection (ECD) ( Ali et al., 1993 and Alves et al., 2009). The HPLC system used is composed of an LC234 
auto-injector, an LC307 delivery pump, an LC142 electro-detector, and a 712 HPLC system controller data 
version 1.30 management software (all supplied by Gilson Medical Electronics HPLC System, Middleton, 
WI). The mobile phase consisted of 70 mM of potassium phosphate monobasic buffer (pH adjusted to 3.0 
by adding phosphoric acid), 1 mM 1-heptanosulfonic acid, 107.5 μM sodium EDTA, and 10% (v/v) of 
methanol. The flow was maintained at 0.8 mL/min. Chromatographic separation was achieved using a 
supercosil LC (7.5 cm × 4.6 cm, 3 μm) reverse phase column. Detection was achieved with an electro-
chemical detector equipped with a glassy carbon-working electrode set at +0.75 V and quantification was 
by external standard method. Protein content was determined using the Bio-Rad Bradford protein assay. 
Results were expressed in ng/mg of protein. Turnover (TO) ratios were calculated as measure of activity 
(metabolites/monoamine). 
2.6. Data analysis 
Anxiety responses were assessed by analyzing the behavioral data collected during the first exposure to the 
object with a one-way ANOVA (group) followed, when appropriate, by Tukey's post hoc test. The delay effect 
on object recognition ability was assessed by ANOVA with repeated measures for delay. Mean differences 
among group were tested for significance by one-way ANOVA followed, when appropriate, by Tukey's post 
hoc test. A paired Student t-test was also performed within group comparisons to demonstrate the presence 
of novelty or familiarity preference by comparing measurement on time spent in exploration of new object to 
that spent in exploration of familiar object. Neurochemical data were analyzed with a one-way ANOVA 
(group), followed, when appropriate, by Tukey's post hoc test. To facilitate data comprehension across the 
result presentation when results refer to differences from the control group the § sign is used, when results 
refer to differences from the MA group the # sign is used, and when results refer to differences from 12 
mounts the + sign is used. All results were analyzed at a significance level of 5%, using the software SPSS 
version 17.0 for Windows. 
3. Results 
3.1. Recognition memory impairment in both MA and aged animals 
Repeated measures ANOVA for delay in terms of total time spent exploring the objects revealed a main 
effect of group [F(3) = 8.82, p < 0.01], and a significant interaction between group and delay 
[F(3) = 3.37,p < 0.05]. The post hoc comparisons revealed that animals from MA group explored more the 
objects at the delay 15 min when compared with the control group, the 12 months group and the 20 months 
group (p < 0.001 for all groups). Concerning the 24 h delay the animals from MA group explored more the 
objects when compared with the 12 months group and the 20 months group (p < 0.05 for both groups). The 
control group explored more the objects in the 24 h delay when compared with both the 12 months and 20 
months groups (p < 0.05). 
Repeated measures ANOVA for the time spent exploring the new object revealed a significant interaction 
between group and delay [F(3) = 5.69, p < 0.01] but not a significant effect for delay. The same analysis for 
the time spent exploring the familiar object showed no effect of delay and no significant interaction between 
group and delay ( Fig. 2). The one-way ANOVA used to evaluate differences among groups showed a main 
effect of group on the time spent exploring the new object [F(3) = 6.87, p < 0.001] and on the time spent 
exploring the familiar object [F(3) = 7.03, p < 0.05]. In the 15 min delay, the post hoc comparisons revealed 
that animals from the MA group explored more, both new (control, 12 months and 20 months: p < 0.01) and 
familiar (control p < 0.05, 12 months p < 0.001, 20 months p < 0.05) objects, when compared with the other 
groups. In the 24 h delay, the post hoc comparisons revealed that control animals explored more the new 
object when compared with the group 12 months (p < 0.01); and the MA group explored more the familiar 




In the 15 min delay, the paired-sample t-test for within group comparisons revealed that all experimental 
groups preferentially (MA, control and 12 months p < 0.001; 20 months p < 0.05) explored the new object. 
At the longer delay, 24 h, only the control group retained this behavior (p < 0.01). 
Statistical analysis of the 24 h delay discriminatory index based on the duration and frequency of the object 
exploration (Fig. 3) revealed a significant effect of group [F(3) = 4.46, p < 0.05] and [F(3) = 2.89, p < 0.05], 
respectively. Indeed, post hoc analysis showed that the discrimination index of MA group was significantly 




3.2. Increased anxiety in MA and aged animals 
The one-way ANOVA of the behavior data collected during the first exposure to the arena revealed a 
significant effect of group in the frequency of object approaches [F(3) = 17.29, p < 0.001]. Post hoc analysis 
showed that the control group presented the highest frequency of approaches, significantly differing from 
the MA (p < 0.05), 12 months (p < 0.001) and 20 months (p < 0.001) groups. The MA group presented a 
significant increase in frequency of object approaches when compared with the 12 months group (p < 0.05). 
The data are presented in Fig. 4. The overall results point to an increased anxiety and neophobic behavior, 
which can be interpreted by the reduced interaction with the object, in both MA and aged animals. 
 
 
3.3. Altered neurotransmission in both MA and aged animals 
To determine whether the present MA exposure paradigm fits the standard decline of neurochemical profile 
associated with aging, monoamines, metabolites and respective turnover ratios were measured. Results 
concerning DA and metabolites are presented in Fig. 5 and results concerning 5HT and 5-
hydroxyindoleacetic acid (5HIAA) are presented in Fig. 6. Data concerning activity levels are represented 











3.3.1. Dopamine and metabolites 
Statistical analysis of DA, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanilic acid (HVA) contents in 
the striatum revealed a significant effect of group 
[F(3) = 5.08, p < 0.01; F(3) = 25.31, p < 0.001;F(3) = 22.98, p < 0.001; respectively]. In the striatum, the 
levels of DA and metabolites (DOPAC and HVA) were generally higher in the control group when compared 
with the respective aged-matched MA group and both aged rat groups (12 and 20 months). The DA levels 
were significantly reduced in the MA group when compared with the control group (26%, p < 0.05). In the 20 
months group, the level of DA was significantly reduced when compared with the control group 
(27%, p < 0.05). The DOPAC level was significantly increased in the control group when compared with both 
the MA group (40%, p < 0.001) and the 20 months group (60%, p < 0.001). When compared with the 12 
months group, both MA and 20 months groups presented reduced DOPAC levels (28%, p < 0.05 and 
53%, p < 0.001, respectively). The HVA level was significantly higher in the control group when compared 
with both the MA group (54%, p < 0.001) and the 20 months group (56%, p < 0.001). When compared with 
the 12 months group, both MA and 20 months groups presented reduced HVA levels (approximately 
58%, p < 0.001 for both). No other significant differences in DA and metabolites levels were found in the 
striatum ( Fig. 5A). 
Statistical analysis of the DOPAC content in the prefrontal cortex revealed a significant effect of group 
[F(3) = 7.69, p < 0.001]. In the prefrontal cortex, the DOPAC level was significantly increased in the 12 
months group when compared with both the MA group (50%, p < 0.01) and the 20 months group 
(56%,p < 0.01). No significant differences between groups were detected concerning DA or HVA levels ( Fig. 
5B). 
Statistical analysis of the DA content in the hippocampus revealed a significant effect of group 
[F(3) = 7.37,p < 0.01]. The DA level in the hippocampus was impaired in all studied groups when comparing 
with the control group. These differences reached significance in both the MA group (56%, p < 0.01) and 20 
months group (55%, p < 0.01). Even though the impairment between the 12 months group and the control 
did not reach significance, a 35% decrease was observed. No significant differences were observed in the 
level of DOPAC when comparing the different studied groups. In the hippocampus, the level of HVA was 
below the detection level of the method ( Fig. 5C). 
3.3.2. Serotonin and 5HIAA 
In the striatum, the levels of 5HT and 5HIAA did not significantly differ between the different studied groups 
(Fig. 6A). 
Statistical analysis of the 5HT content in the prefrontal cortex revealed a significant effect of group 
[F(3) = 4.34, p < 0.05]. The 5HT level in the prefrontal cortex of control animals presented the highest value, 
reaching a significant difference with the 20 months group (45%, p < 0.05). The impairment of 37% observed 
in the MA group did not reach significance. In the prefrontal cortex, the level of 5HIAA was not significantly 
different between the studied groups ( Fig. 6B). 
Statistical analysis of the serotonin and 5HIAA contents in the hippocampus revealed a significant effect of 
group [F(3) = 6.61, p < 0.01; F(3) = 20.58, p < 0.001; respectively]. In the hippocampus, an impaired level 
of 5HT was observed in the MA group when compared with both the control group (65%, p < 0.05) and the 
12 months group (64%, p < 0.05). Concerning the 5HIAA values, the highest level was observed in the 
control group. The difference was significant when compared with both the MA group (58%, p < 0.001) and 
the 20 months group (40%, p < 0.001). Still considering 5HIAA contents, a significant impairment in the MA 
group when compared with 12 months group (46%, p < 0.001) was also observed ( Fig. 6C). 
3.3.3. Turnover (TO) ratios 
The different DA TO ratios [DOPAC/DA, HVA/DA, and (DOPAC + HVA)/DA] and 5HT TO ratio (5HIAA/5HT) 
were calculated in the different brain regions (Table 1). 
Statistical analysis of DA TO ratios in the striatum revealed a significant effect of group 
[F(3) = 7.66,p = <0.01; F(3) = 15.45, p < 0.001; F(3) = 12.29, p < 0.001; respectively]. In the striatum, the 
highest HVA/DA ratios were observed in the control and in the 12 months groups. The impairment between 
the MA group and the control group, and between the 20 months and control group reached significance 
(both 43%, p < 0.05). In the MA and the 20 months groups, the HVA/DA ratios were significantly impaired 
when compared with the 12 months group (approximately 55%, p < 0.001 for both). Concerning 
(DOPAC + HVA)/DA, the 12 months group presented the highest value, even though not significantly 
differing from the control group. When compared with the 12 months group, both the MA and the 20 months 
groups displayed impairments (30%, p < 0.001 and 48%, p < 0.001; respectively). The decrease observed 
between the control group and the Age2 group also reached a significant level (45%, p < 0.05). No other 
significant differences between groups were observed in the TO ratios in the striatum. 
Statistical analysis of DA TO ratios in the prefrontal cortex revealed a significant effect of group 
[F(3) = 5.83, p < 0.05; F(3) = 6.17, p < 0.05; DOPAC/DA and (DOPAC + HVA)/DA respectively]. In the 
prefrontal cortex, the highest DOPAC/DA ratio was observed in the 12 months group even though not 
significantly differing from the control group. Both the MA and 20 months groups presented significantly 
lower TO ratios when compared with the 12 months group (45%, p < 0.05 and 56%, p < 0.001). The lowest 
(DOPAC + HVA)/DA ratio was observed in the 20 months group. This value is significantly different from the 
control group (43%, p < 0.05) and the 12 months group (46%, p < 0.05). Statistical analysis of the 5HT TO 
ratio in the prefrontal cortex revealed a significant effect of group [F(3) = 3.142, p = 0.04]. The 5HIAA/5HT 
TO ratio was significantly different between the control group and the 20 months group (35%,p = 0.031). No 
further significant differences were observed. 
None of the TO ratios calculated with reference to the hippocampus presented statistical differences 
between the studied groups. 
4. Discussion 
In the present study we investigated the memory performance of Wistar rats repeatedly exposed to MA, 
when compared with both an age-matched control group and with chronologically aged animals. Additionally, 
we determined the levels of monoamines and their metabolites in the prefrontal cortex, hippocampus and 
the striatum, brain regions known to be involved in the memory function. The key findings are that repeated 
exposure to MA results in a loss of long, but not short, time object recognition memory and a depletion of 
monoamines and their metabolites. The results closely matched those obtained in the aged animal groups. 
We found that extended treatment with MA induced a general exploration increase when compared with 
both the age-matched control group and the aged animal groups. These results are in contrast with previous 
studies that reported, depending on the analyzed delay, either no change, or a decreased activity, in MA-
treated animals (Boger et al., 2007 and Boger et al., 2009). The differences may relate to the different drug 
administration paradigm and also the different species used. The exploration reduction observed in the aged 
groups is, however, in agreement with a previous report (Bergado et al., 2011). According to the present 
study, when a new object is introduced after a 15 min delay in the arena, all animals equally engage 
themselves in exploration activities and are able to detect novelty, a finding supported by previous work 
(Bergado et al., 2011). Nevertheless, it is interesting to note that even though MA-treated animals and aged 
animals recognized novelty in the short time delay (15 min), when the period between the presentation of 
objects was increased (24 h) these groups lost the ability to recognize different objects. Increasing the time 
between the presentation of the familiar and the new object rendered aged animals unable to recognize 
novelty (Luparini et al., 2000). 
The initial behavior of the tested animals (first day of habituation) revealed an increased frequency of 
approaches to the object by the MA age-matched control group when compared with the MA and the aged 
groups, which may possibly be interpreted as a less neophobic behavior. This reduced behavior in MA and 
aged animals may also be related to an increased preference to move along the walls when exploring a new 
environment (thigmotaxis). The higher frequency of approaches to the object in the first exposure to the 
apparatus may manifest a less anxiogenic response by the control group when compared with both the MA 
group and the aged groups. This neophobic behavior may be linked to a previously reported MA-induced 
thigmotaxis and may also serve as a valid indication of an anxiety-like state (Camarasa et al., 2010 and Treit 
and Fundytus, 1988). Our findings concerning the performance of the aged animals in the first exposure to 
the arena are in agreement with reports of increased anxiety among aged rats in the elevated T-maze 
(Boguszewski and Zagrodzka, 2002). 
It has previously been shown, both in animals and humans, that repeated MA exposure results in long-term 
functional changes to the dopaminergic and serotonergic systems (Chang et al., 2007 and Volz et al., 2007). 
Nevertheless, assessing the nature of these changes (neuronal damage versus compensatory adaptations) 
is not always straightforward. In the current study, levels of DA, 5HT and their metabolites were determined 
after a prolonged withdrawal from binge repeated MA administration. In agreement with early work (Wagner 
et al., 1980b), the MA exposure paradigm used in the present study profoundly altered the dopaminergic 
system in the striatum, with a consistent depletion of DA and related metabolites. Corroborating previous 
reports (Miguez et al., 1999 and Ossowska, 1993), we observed an aged-related decline of the same 
dopaminergic parameters. These alterations, which occur during the aging of the brain and also during age-
related neurodegenerative processes such as Parkinson's and Alzheimer's diseases, have been associated 
with MA misuse (Garwood et al., 2006 and Guilarte, 2001). Indeed, the cellular mechanisms of the DA 
precursor L-3,4-dihydroxyphenylalanine (L-DOPA), which is the classic therapy used in Parkinson's disease, 
shows major similarities with MA (Biagioni et al., 2009). 
Changes in DOPAC, HVA or TO ratios have been used to estimate dopaminergic transmission, with lower 
production of DOPAC and HVA and reduced TO indicating reduced transmission. In the present study, the 
HVA:DA ratio was consistently reduced in both the MA and aged groups when compared to the control 
group. Previous studies, using extended MA self-administration in rats, have also reported a reduced 
dopaminergic activity, which occurs simultaneously with DA transporter down regulation (Schwendt et al., 
2009). The (DOPAC + HVA)/DA ratio was only impaired in an age-dependent manner. These results are in 
agreement with previous studies that reported a decrease in the striatal DA TO in aged rats (Carfagna et al., 
1985, Ponzio et al., 1978 and Venero et al., 1991). The well-known loss of dopaminergic neurons that project 
to the striatum may be linked to the above mentioned scenario (Kish et al., 1992). Indeed, the DA decrease 
observed during aging may relate to the decrease in tyrosine hydroxylase activity, with downstream 
repercussions at the level of DA synthesis (Reis et al., 1977). Similar consequences result from repeated 
MA exposure (Frost and Cadet, 2000, Harvey et al., 2000, Seiden et al., 1993, Sekine et al., 
2001 and Volkow et al., 2001). 
The hippocampus receives dopaminergic innervations mainly through the mesolimbic tract, which originates 
in the ventrotegmental region (Gasbarri et al., 1994). Previously, it has been suggested that hippocampal 
and striatal DA contents are similarly affected by age, while in other brain regions such as the prefrontal 
cortex, the dopaminergic content remains unchanged (Miguez et al., 1999). In the present work, we too 
report an age-related impairment in DA content in the hippocampus, but not in the prefrontal cortex. In the 
prefrontal cortex, we only observed an age-related decline in the levels of DOPAC and DA TO. It is important 
to note that we found similar results for the aged and MA groups concerning DA. Previous data support 
these findings; indeed, the relation between MA neurotoxicity and DA impairment in different brain regions 
has long been established (Friedman et al., 1998 and Sabol et al., 2001). 
MA also affects the serotonergic system. The first reports assessing this issue noted significant depletion of 
5HT, with an associated loss of 5HT transporters, 3 weeks after the cessation of treatment (Ricaurte et al., 
1980), and a reduction in tryptophan hydroxylase activity in the striatum and hippocampus after 1 month of 
the MA treatment (Hotchkiss and Gibb, 1980). In our work, MA-related 5HT contents and respective TO 
were only impaired in the hippocampus, not the striatum. With respect to the age-related alterations in the 
serotonergic system, the published literature is inconsistent. There are reports of unchanged (Moretti et al., 
1987, Ponzio et al., 1982 and Pradhan, 1980), increased (Santiago et al., 1988 and Venero et al., 1993), or 
decreased (Venero et al., 1991) 5HT content and 5HT TO ratio. Concerning the 5HT content, our results 
show an age-related impairment in the prefrontal cortex. The 5HIAA content presented an age-related 
impairment in the hippocampus. 5HT TO was elevated in older animals, which is in agreement with previous 
data (Miguez et al., 1999), and may reflect an age-dependent increase in oxidative deamination occurring 
in the 5HT terminal areas in opposition to a lower synthesis of the amine. 
Recent studies have correlated striatum, prefrontal cortex and hippocampus dopamine and serotonin deficits 
produced either by a repeated MA exposure (Lu et al., 2010) or observed in aged (20 months) rats (Esteban 
et al., 2010a and Esteban et al., 2010b) with cognitive deficits, corroborating the data presented here. 
Indeed, Lu and colleagues report an impairment of DA in the prefrontal cortex and an impairment in 5HT in 
the hippocampus in male mice with cognitive deficits (Lu et al., 2010). Esteban and colleagues also observed 
deficits in DA, 5HT and metabolites in the striatum and hippocampus in aged rats with cognitive impairments 
(Esteban et al., 2010a). 
5. Conclusion 
MA chronic exposure has been previously linked with schizophrenia's recognition memory deficits (Simon 
et al., 2000) and has been used to model this condition, overall, the present set of data also demonstrates 
that MA administration largely mimics the complex effects of chronological aging on the neurotransmitter 
systems, with similar alterations in object recognition memory. The striatum, prefrontal cortex and 
hippocampus are target brain regions actively involved in both MA- and age-related neurodegenerative 
processes, including cognitive and learning impairments that may be associated with Dementia, Parkinson's 
and Alzheimer's diseases. Understandably, research in this field has major social and medical relevance. 
MA-induced “accelerated aging” would increase the burden of elderly care. The present work contributes to 
the development of a feasible animal model to study the neuronal processes associated with aging. 
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